ArticleCancer immunology, immunotherapy : CII2011
Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?
Article in Cancer immunology, immunotherapy : CII, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy.Molecular medicine (Cambridge, Mass.) · 2025Review
- Expression of four cancer-testis antigens in TNBC indicating potential universal immunotherapeutic targets.Journal of cancer research and clinical oncology · 2023Article
- Cancer Immunoprevention: Current Status and Future Directions.Archivum immunologiae et therapiae experimentalis · 2021Review
- Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention.Cancer immunology research · 2020Article
- Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression.Oncology letters · 2020Article
- Expression of tumor-associated antigens in breast cancer subtypes.Breast (Edinburgh, Scotland) · 2020Article
- A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.Journal for immunotherapy of cancer · 2017Article
- Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Pharmacology & therapeutics · 2017Review
- Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.Oncotarget · 2017Article
- Human Tumor Antigens Yesterday, Today, and Tomorrow.Cancer immunology research · 2017Review
- Cancer immunoprevention.Current opinion in immunology · 2016Review
- Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis.Breast cancer research and treatment · 2014Article
- Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.International journal of clinical and experimental pathology · 2014Article
- Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.Breast cancer research : BCR · 2013Review
- Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.Molecular & cellular proteomics : MCP · 2013Article
- Expression of Testis Specific Genes TSGA10, TEX101 and ODF3 in Breast Cancer.Iranian Red Crescent medical journal · 2012Article
- Potential use of vaccines in the primary prevention of breast cancer in high-risk patients.Breast care (Basel, Switzerland) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
Abstract
introductionNovel breast cancer risk-reducing strategies for individuals with germline mutations of the BRCA1 and/or BRCA2 genes are urgently needed. Identification of antigenic targets that are expressed in early cancers, but absent in normal breast epithelium of these high-risk individuals, could provide the basis for the development of effective immunoprophylactic strategies. Cancer testis (CT) antigens are potential candidates because their expression is restricted to tumors, and accumulating data suggest that they play important roles in cellular proliferation, stem cell function, and carcinogenesis. The objective of this study was to examine the expression of CT antigens and their frequency in BRCA-associated breast cancers.
methodsArchived breast cancer tissues (n = 26) as well as morphologically normal breast tissues (n = 7) from women carrying deleterious BRCA 1 and/or 2 mutations were obtained for antigen expression analysis by immunohistochemistry. Expression of the following CT antigens was examined: MAGE-A1, MAGE-A3, MAGE-A4, MAGE-C1.CT7, NY-ESO-1, MAGE-C2/CT10, and GAGE.
resultsCT antigens were expressed in 16/26 (61.5%, 95% CI 43-80%) of BRCA-associated cancers, including in situ tumors. Thirteen of twenty-six (50%) breast cancers expressed two or more CT antigens; three cancers expressed all seven CT antigens. MAGE-A was expressed in 13/26 (50%) of cancers, NY-ESO-1 was expressed in 10/26 (38%) of tumors. In contrast, none of the CT antigens were expressed in adjacent or contralateral normal breast epithelium (P = 0.003).
conclusionsWe report a high CT antigen expression rate in BRCA-associated breast cancer as well as the lack of expression of these antigens in benign breast tissue of carriers, identifying CT antigens as potential vaccine targets for breast cancer prevention in these high-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.